Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Akebia Therapeutics
Age
0–16
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of anemia of chronic kidney disease (CKD)
Diagnosis of non-dialysis-dependent (NDD) CKD with an estimated glomerular filtration rate of greater than (\>) 10 and less than (\<) 60 milliliters/minute/1.73 meters\^2 (mL/min/1.73 m\^2) or diagnosis of dialysis dependent (DD) CKD
Mean hemoglobin (Hb) between 9.0 and 12.0 grams/deciliters (g/dL) (inclusive)
Transferrin Saturation ≥ 20%
You may not be if
Anemia due to a cause other than CKD
Active bleeding or recent clinically significant blood loss
History of sickle cell disease, myelodysplastic syndromes, bone marrow fibrosis, hematologic malignancy, myeloma, hemolytic anemia, thalassemia, or pure red cell aplasia
Red Blood Cells transfusion within 4 weeks
Serum albumin level less than 2.5 g/dL
Uncontrolled hypertension
Active malignancy or treatment for malignancy within the past 2 years prior to Screening
Evidence of iron overload or diagnosis of hemochromatosis
Known hypersensitivity to vadadustat or any excipients in vadadustat tablet
